M&T Bank Corp Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

M&T Bank Corp lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 2.5% in the fourth quarter, HoldingsChannel reports. The firm owned 37,780 shares of the medical device company’s stock after buying an additional 937 shares during the period. M&T Bank Corp’s holdings in DexCom were worth $2,939,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Versant Capital Management Inc purchased a new stake in shares of DexCom in the fourth quarter valued at about $25,000. Private Trust Co. NA grew its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the period. Heck Capital Advisors LLC purchased a new stake in shares of DexCom in the fourth quarter valued at about $38,000. SBI Securities Co. Ltd. acquired a new position in DexCom in the fourth quarter valued at about $49,000. Finally, Midwest Capital Advisors LLC acquired a new position in DexCom in the fourth quarter valued at about $54,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Citigroup upped their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Wells Fargo & Company upped their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,083 shares of company stock worth $3,309,794. Company insiders own 0.30% of the company’s stock.

DexCom Stock Down 2.1 %

DXCM stock opened at $77.84 on Friday. The company’s 50 day moving average price is $84.83 and its 200 day moving average price is $76.99. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a market capitalization of $30.42 billion, a price-to-earnings ratio of 54.43, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.